Trials / Conditions / Progressive Familial Intrahepatic Cholestasis

Progressive Familial Intrahepatic Cholestasis

15 registered clinical trials studyying Progressive Familial Intrahepatic Cholestasis — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE NCT07317193	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	N/A
Recruiting	A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intr NCT07185919	Ipsen	—
Recruiting	Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis NCT06781242	IRCCS Azienda Ospedaliero-Universitaria di Bologna	—
Recruiting	Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) NCT06193928	Mirum Pharmaceuticals, Inc.	—
Recruiting	Prospective Analysis of the Treatment of Progressive Familial Intrahepatic Cholestasis (TreatFIC) NCT06778174	University Medical Center Groningen	—
Unknown	Progressive Familial Intrahepatic Cholestasis in Indian Children - Establishing an Indian PFIC Registry NCT05704517	Institute of Liver and Biliary Sciences, India	—
Completed	Baby Detect : Genomic Newborn Screening NCT05687474	Centre Hospitalier Universitaire de Liege	—
Completed	A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver D NCT04729751	Mirum Pharmaceuticals, Inc.	Phase 2
Unknown	Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders NCT04071197	National Liver Institute, Egypt	N/A
Completed	Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC NCT03659916	Albireo, an Ipsen Company	Phase 3
Completed	An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects NCT03082937	Albireo	Phase 1
Enrolling By Invitation	NAtural Course and Prognosis of PFIC and Effect of Biliary Diversion NCT03930810	University Medical Center Groningen	—
Completed	Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease NCT02131623	Mirum Pharmaceuticals, Inc.	—
Completed	A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 NCT02963077	Albireo	Phase 1
Approved For Marketing	Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis NCT04483531	Albireo	—